JPH10310535A5 - - Google Patents

Info

Publication number
JPH10310535A5
JPH10310535A5 JP1997157645A JP15764597A JPH10310535A5 JP H10310535 A5 JPH10310535 A5 JP H10310535A5 JP 1997157645 A JP1997157645 A JP 1997157645A JP 15764597 A JP15764597 A JP 15764597A JP H10310535 A5 JPH10310535 A5 JP H10310535A5
Authority
JP
Japan
Prior art keywords
organ failure
multiple organ
preventive
burn
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997157645A
Other languages
English (en)
Other versions
JPH10310535A (ja
JP4006058B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from JP15764597A external-priority patent/JP4006058B2/ja
Priority to JP15764597A priority Critical patent/JP4006058B2/ja
Priority to DE69839621T priority patent/DE69839621D1/de
Priority to PCT/JP1998/000998 priority patent/WO1998040096A1/ja
Priority to ES98907158T priority patent/ES2308802T3/es
Priority to AU63092/98A priority patent/AU725441B2/en
Priority to EP98907158A priority patent/EP0914829B1/en
Priority to AT98907158T priority patent/ATE398460T1/de
Priority to CA002252711A priority patent/CA2252711A1/en
Priority to US09/180,599 priority patent/US20010051146A1/en
Publication of JPH10310535A publication Critical patent/JPH10310535A/ja
Priority to US10/317,011 priority patent/US7306791B2/en
Publication of JPH10310535A5 publication Critical patent/JPH10310535A5/ja
Publication of JP4006058B2 publication Critical patent/JP4006058B2/ja
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Claims (4)

  1. 腫瘍細胞壊死因子−II（Tumor cytotoxic factor−II; ＴＣＦ−II) を有効成分とする多臓器不全予防及び／又は治療剤。
  2. 多臓器不全が感染症、カヘキシー、肝腎障害、虚血性障害、急性膵炎、または熱傷を原因とする多臓器不全である請求項１記載の剤。
  3. 肝細胞増殖因子(hepatocyte growth factor;ＨＧＦ) を有効成分とする多臓器不全予防及び／又は治療剤。
  4. 多臓器不全が感染症または熱傷を原因とする多臓器不全である請求項３記載の剤。
JP15764597A 1997-03-11 1997-05-30 多臓器不全予防及び／又は治療剤 Expired - Fee Related JP4006058B2 (ja)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP15764597A JP4006058B2 (ja) 1997-03-11 1997-05-30 多臓器不全予防及び／又は治療剤
AT98907158T ATE398460T1 (de) 1997-03-11 1998-03-11 Vorbeuge- und/oder heilmittel für das multiple organversagen
US09/180,599 US20010051146A1 (en) 1997-03-11 1998-03-11 Agent for preventing and/or treating multiple organ failure
ES98907158T ES2308802T3 (es) 1997-03-11 1998-03-11 Agentes preventivos y/o remedios para la insuficiencia multiorganica.
AU63092/98A AU725441B2 (en) 1997-03-11 1998-03-11 An agent for preventing and/or treating multiple organ failure
EP98907158A EP0914829B1 (en) 1997-03-11 1998-03-11 Preventives and/or remedies for multiple organ failure
DE69839621T DE69839621D1 (de) 1997-03-11 1998-03-11 Anversagen
CA002252711A CA2252711A1 (en) 1997-03-11 1998-03-11 An agent for preventing and/or treating multiple organ failure
PCT/JP1998/000998 WO1998040096A1 (en) 1997-03-11 1998-03-11 Preventives and/or remedies for multiple organ failure
US10/317,011 US7306791B2 (en) 1997-03-11 2002-12-11 Agent for preventing and/or treating multiple organ failure

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP9-74372 1997-03-11
JP7437297 1997-03-11
JP15764597A JP4006058B2 (ja) 1997-03-11 1997-05-30 多臓器不全予防及び／又は治療剤

Publications (3)

Publication Number Publication Date
JPH10310535A JPH10310535A (ja) 1998-11-24
JPH10310535A5 true JPH10310535A5 (ja) 2005-03-03
JP4006058B2 JP4006058B2 (ja) 2007-11-14

Family

ID=26415513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP15764597A Expired - Fee Related JP4006058B2 (ja) 1997-03-11 1997-05-30 多臓器不全予防及び／又は治療剤

Country Status (9)

Country Link
US (2) US20010051146A1 (ja)
EP (1) EP0914829B1 (ja)
JP (1) JP4006058B2 (ja)
AT (1) ATE398460T1 (ja)
AU (1) AU725441B2 (ja)
CA (1) CA2252711A1 (ja)
DE (1) DE69839621D1 (ja)
ES (1) ES2308802T3 (ja)
WO (1) WO1998040096A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4006058B2 (ja) 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
ES2274567T3 (es) 1997-03-14 2007-05-16 Daiichi Pharmaceutical Co., Ltd. Utilizacion de tcf-ii para el tratamiento de la perdida de peso corporal, la anemia y la elevacion de tnf causadas por el cancer.
JPH1129493A (ja) * 1997-07-14 1999-02-02 Snow Brand Milk Prod Co Ltd 放射線障害予防及び／又は治療剤
CA2410918A1 (en) * 2000-06-02 2002-11-29 Hiroshi Okamoto Agents for proliferating pancreatic beta-cells of the islets of langerhans, agents for suppressing apoptosis of said cells, and screening of candidate compounds for these agents
GB0110430D0 (en) * 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
WO2003037365A1 (en) * 2001-11-01 2003-05-08 The Johns Hopkins University Methods and compositions for treating vascular leak using hepatocyte growth factor

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904753A (en) 1970-02-20 1975-09-09 Research Corp Clinically active bovine growth hormone fraction
US4076701A (en) 1975-07-29 1978-02-28 Immunology Research Foundation, Inc. Tumor complement fraction recovery method and product
US4490549A (en) 1977-04-19 1984-12-25 The Upjohn Company Enlarged-hetero-ring prostacyclin analogs
US4481137A (en) 1982-02-26 1984-11-06 Mochida Pharmaceutical Co., Ltd. Glycoproteins and processes for their production
JPS60112718A (ja) 1983-11-21 1985-06-19 Kyorin Pharmaceut Co Ltd 抗腫瘍作用を示す蛋白性物質及びその製造方法
US4650674A (en) 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
ATE41159T1 (de) 1985-08-29 1989-03-15 Berol Kemi Ab Traeger mit einer immobilisierten biologischaktiven substanz, verfahren zur herstellung und seine verwendung.
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4822605A (en) 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
KR890009412A (ko) 1987-12-22 1989-08-01 마쓰시따 렌조오 종양 세포 억제 인자
JPH0296598A (ja) 1988-10-03 1990-04-09 Sapporo Breweries Ltd リンフォカイン活性化キラー細胞誘導抑制因子ｌａｋｓｆ，その製造法およびそれを有効成分とする免疫抑制剤
NZ232813A (en) 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
US5035887A (en) 1989-09-07 1991-07-30 Institute Of Moelcular Biology, Inc. Wound healing composition of IL-1 and PDGF or IGF-1
US5362716A (en) 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
US5648273A (en) 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
JP2784455B2 (ja) 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
DE69133492T2 (de) 1990-06-11 2006-08-10 Nakamura, Toshikazu Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
JP2750372B2 (ja) * 1990-06-19 1998-05-13 敏一 中村 賢疾患治療剤
ATE178354T1 (de) 1990-07-13 1999-04-15 Snow Brand Milk Products Co Ltd Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung
US5821223A (en) 1990-09-14 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating cell growth with a novel broad spectrum human lung fibroblast-derived mitogen
IL100899A (en) 1991-02-08 1997-06-10 Sankyo Co Beta-amino-alpha- hydroxycarboxylic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JPH0597A (ja) 1991-06-21 1993-01-08 Snow Brand Milk Prod Co Ltd 新規抗ｔｃｆ−ｉｉモノクローナル抗体及びそれを用いるｔｃｆ−ｉｉの測定方法
JP3394982B2 (ja) 1991-11-07 2003-04-07 敏一 中村 ガン療法用副作用防止剤
WO1993013066A1 (en) 1991-12-20 1993-07-08 Syntex (U.S.A.) Inc. Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors
JP3123617B2 (ja) 1992-03-04 2001-01-15 雪印乳業株式会社 シアル酸結合を有する化合物の製造法
JPH0625273A (ja) * 1992-03-31 1994-02-01 Dai Ichi Seiyaku Co Ltd アミノ糖誘導体
NO178729C (no) 1992-03-31 1996-05-22 Daiichi Seiyaku Co Terapeutisk aktive sukkerderivater
US5315000A (en) 1992-05-14 1994-05-24 Children's Hospital Medical Center Gene encoding for a L5/3 growth factor and its CDNA
WO1993023541A1 (en) 1992-05-18 1993-11-25 Genentech, Inc. Hepatocyte growth factor variants
AU674871B2 (en) 1992-07-16 1997-01-16 Atlas Pharmaceuticals Inc. Blood coagulation normalizer containing TCF-II as active ingredient
JPH0656692A (ja) * 1992-08-10 1994-03-01 Snow Brand Milk Prod Co Ltd Ｔｃｆ−ｉｉを有効成分とする創傷治療剤
JP3380573B2 (ja) * 1992-07-16 2003-02-24 第一製薬株式会社 Ｔｃｆ−ｉｉを有効成分とする蛋白合成促進剤
JP3619526B2 (ja) 1992-07-16 2005-02-09 第一製薬株式会社 Ｔｃｆ−ｉｉを有効成分とする肝臓疾患治療剤
DK0588477T3 (da) * 1992-07-16 1998-03-30 Snow Brand Milk Products Co Ltd Medicinsk præparat omfatende TCF-11
JP3697460B2 (ja) * 1992-07-17 2005-09-21 敏一 中村 Ｈｇｆ含有製剤
AU662434B2 (en) 1992-08-07 1995-08-31 Sankyo Company Limited Peptides capable of inhibiting the activity of HIV protease, their preparation and their use
JP3402476B2 (ja) 1992-08-24 2003-05-06 生化学工業株式会社 リポ多糖結合性タンパク質及びその製造法
DE69310525T2 (de) 1992-09-16 1997-10-02 Genentech Inc Schutz gegen leberschäden mit hgf
US5703047A (en) 1992-09-21 1997-12-30 Board Of Regents, The University Of Texas System Methods and treatments for corneal healing with growth factors
US5589451A (en) 1992-09-21 1996-12-31 Board Of Regents, The University Of Texas System Methods and treaments for corneal healing with hepatocyte and keratinocyte growth factors
JPH06116299A (ja) 1992-10-02 1994-04-26 Snow Brand Milk Prod Co Ltd 特定の糖鎖構造により高い生物活性を有する遺伝子組換え型ｔｃｆ
US5554653A (en) 1992-12-22 1996-09-10 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
MX9308016A (es) 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
WO1994014845A1 (en) 1992-12-28 1994-07-07 Snow Brand Milk Products Co., Ltd. Modified tcf
JP3552240B2 (ja) 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
JPH07258298A (ja) 1994-03-18 1995-10-09 Snow Brand Milk Prod Co Ltd モノクローナル抗体
JP3962097B2 (ja) 1994-03-18 2007-08-22 敏一 中村 免疫抑制剤による副作用の軽減剤
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
DE69531673T2 (de) 1994-12-27 2004-07-08 Daiichi Pharmaceutical Co., Ltd. Tcf mutante
NZ298141A (en) * 1994-12-27 2000-12-22 Snow Brand Milk Products Co Ltd Treating lipid metabolism disorder using TCF-II
JPH08231418A (ja) 1995-02-24 1996-09-10 Mitsubishi Chem Corp 腸疾患治療剤
AU4953796A (en) 1995-03-15 1996-10-02 Sanyko Company, Limited Dipeptide compounds having ahpba structure
JP3859710B2 (ja) 1995-04-21 2006-12-20 三菱化学株式会社 虚血性疾患の予防及び／又は治療剤
JPH10194986A (ja) 1996-06-10 1998-07-28 Snow Brand Milk Prod Co Ltd 移植肝機能改善・再生促進剤
JP3887435B2 (ja) 1996-07-12 2007-02-28 第一製薬株式会社 スフェロイド形成促進剤
JPH1068400A (ja) 1996-08-28 1998-03-10 Tetsuo Taira 液体を押し出すボトルポンプ及びその方法と製造方法
JP4006058B2 (ja) 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
ES2274567T3 (es) 1997-03-14 2007-05-16 Daiichi Pharmaceutical Co., Ltd. Utilizacion de tcf-ii para el tratamiento de la perdida de peso corporal, la anemia y la elevacion de tnf causadas por el cancer.
JP3961064B2 (ja) 1997-03-28 2007-08-15 第一製薬株式会社 腎疾患予防及び／又は治療剤
JPH1129493A (ja) 1997-07-14 1999-02-02 Snow Brand Milk Prod Co Ltd 放射線障害予防及び／又は治療剤
JPH11269091A (ja) 1998-03-19 1999-10-05 Snow Brand Milk Prod Co Ltd 敗血症予防及び／又は治療剤

Similar Documents

Publication Publication Date Title
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
JP2002532112A5 (ja)
SE9903759D0 (sv) Pharmaceutically active compounds
DK1287822T3 (da) Orale farmaceutiske mesalazinsammensætninger med kontrolleret frigivelse
ATE486840T1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
IS4265A (is) Afleiður af mycophenolicsýrum, sem hafa efnahópa tengda-N-atómi í stöðu 6
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
RU95101836A (ru) Производные 1н-3-арил-пирролидин-2,4-диона, смесь их изомеров или отдельные изомеры и средство для борьбы с вредителями
RU95101048A (ru) Производные пролинамида, фармкомпозиция на их основе
EE200100693A (et) Uus ravimvorm
CA2386690A1 (en) Pharmaceutical tramadol salts
ES2182357T3 (es) Nueva utilizacion de budesonide y formoterol.
TR200200883T2 (tr) 2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
ITGE930016A0 (it) Sistema elettrochirurgico trequarti,cosidetto "trocar".
JP2000159790A5 (ja)
CO5720000A2 (es) Derivados de macrolidos con actividad antiinflamatoria, su procedimiento de sintesis y composiciones farmaceuticas que los contienen
JPH09188680A5 (ja)
DE69706825D1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
JP2001513504A5 (ja)
JP2002542281A5 (ja)
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
CA2091134A1 (en) Therapeutic agent for threatened abortion
CA2382548A1 (en) Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof
JP2002523361A5 (ja)
IT1240799B (it) Composizioni farmaceutiche contenenti 3-metiltiopropionil l-carnitina ad attivita' sul sistema cardiovascolare.